Adma Biologics (ADMA) Net Income Growth (1y) (2012 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 12.59% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -115.33% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -73.01% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,228.66% |
| 10 | Adma Biologics | 1.90 Bn | 1.81 Bn | 88.82 Mn | -55.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -55.87% |
| Sep 30, 2025 | 1.45% |
| Jun 30, 2025 | 6.73% |
| Mar 31, 2025 | 51.10% |
| Dec 31, 2024 | 956.22% |
| Sep 30, 2024 | 1,299.96% |
| Jun 30, 2024 | 603.25% |
| Mar 31, 2024 | 362.28% |
| Dec 31, 2023 | 189.84% |
| Sep 30, 2023 | 117.23% |
| Jun 30, 2023 | 53.65% |
| Mar 31, 2023 | 62.64% |
| Dec 31, 2022 | 28.55% |
| Sep 30, 2022 | 16.03% |
| Jun 30, 2022 | 26.97% |
| Mar 31, 2022 | 0.91% |
| Dec 31, 2021 | 18.74% |
| Sep 30, 2021 | -4.98% |
| Jun 30, 2021 | -10.00% |
| Mar 31, 2021 | 4.68% |
| Dec 31, 2020 | -95.74% |
| Sep 30, 2020 | -47.93% |
| Jun 30, 2020 | -29.61% |
| Mar 31, 2020 | -31.58% |
| Dec 31, 2019 | 42.12% |
| Sep 30, 2019 | 24.48% |
| Jun 30, 2019 | 10.46% |
| Mar 31, 2019 | 17.99% |
| Dec 31, 2018 | -52.40% |
| Sep 30, 2018 | 0.56% |
| Jun 30, 2018 | -63.16% |
| Mar 31, 2018 | -172.74% |
| Dec 31, 2017 | -158.00% |
| Sep 30, 2017 | -251.00% |
| Jun 30, 2017 | -50.19% |
| Mar 31, 2017 | -41.72% |
| Mar 31, 2013 | -442.70% |
| Dec 31, 2012 | -135.82% |
| Sep 30, 2012 | -230.84% |
| Jun 30, 2012 | 49.45% |
| Mar 31, 2012 | 62.20% |